Merck & Co., Inc. (NYSE:MRK) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a decline in revenue in the second quarter of 2025, the company received the FDA approval for KEYTRUDA QLEX™ injection. Merck Gains FDA Approval for KEYTRUDA QLEX™ and Supports Dividend Appeal Merck & Co., Inc. (NYSE:MRK) reported an Adjusted EPS of $2.13 for the second quarter of 2025. The reported value surpasses the $2.03 consensus, projecting a positive perception towards its operational efficiency ...